Syntaxin Ltd.
This article was originally published in Start Up
Executive Summary
Syntaxin is developing bacterial-based biotherapeutic proteins that control cell secretion as potential treatments for neurological, respiratory and metabolic diseases. A team of 13 scientists spun Syntaxin out from the UK's Health Protection Agency (HPA) in November 2005.
You may also be interested in...
Start-Up Previews (03/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Do-It-Yourself Dermatology, features profiles of Therative and Xthetix. Plus these Start-Ups Across Health Care: iCardiac Technologies, Jenken Biosciences, Neovasc Medical, and Syntaxin.
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.